<DOC>
	<DOCNO>NCT00832377</DOCNO>
	<brief_summary>A study evaluate effect 12-week treatment timolol/dorzolamide combination eyedrop ( COSOPT ) decrease intraocular pressure ( IOP ) 2 hour study drug administration</brief_summary>
	<brief_title>COSOPT ( Timolol/Dorzolamide Combination ) Normal Tension Glaucoma Study ( MK0507A-161 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Low Tension Glaucoma</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Dorzolamide</mesh_term>
	<criteria>Patients treat glaucoma medication within 6 week prior study participation diagnosis primary openangle glaucoma Patients primary openangle glaucoma base gonioscopy Patients normal tension glaucoma diagnose base accompany optic disc cup reappearance visual field defect correspond retinal nerve fiber layer defect . Subjects &lt; 22 mm Hg diurnal IOP measure use Goldmann applanation tonometer ( every two hour 9 a.m. 5 p.m. ) Patients another type glaucoma primary openangle glaucoma Patients treat glaucoma medication within 6 week prior study participation Patients history chronic ocular inflammation recurrent ocular inflammation Patients use contact lens Patients allergic timolol dorzolamide Patients history follow COSOPT ( timolol/dorzolamide combination ) contraindication : Reactive airway disease Sinus bradycardia , second third degree atrioventricular block , overt cardiac failure , cardiogenic shock Severe renal impairment Patients history significant ocular trauma intraocular surgery within 6 month participate study , intraocular laser surgery within 3 month participate study Patients history corneal disease Patients use steroid use drug 2 week within 12 month participate study Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>